{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T10:05:04Z","timestamp":1787652304221,"version":"build-2736575974"},"reference-count":90,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Background: Precision oncology has traditionally relied on genomic biomarkers to guide therapy selection; however, static molecular profiling often fails to predict real-world responses to cytotoxic chemotherapy. Increasing evidence suggests that treatment outcomes are determined by the interaction between tumor-intrinsic biology and host-specific pharmacology. Functional ex vivo platforms, including patient-derived organoids and tumor slice cultures, provide a complementary phenotypic readout of drug sensitivity that reflects tumor architecture and microenvironmental interactions. Methods: This narrative review integrates recent experimental, translational, and clinical evidence on molecular oncodiagnostics combining tumor transcriptomics, germline pharmacogenetics, and ex vivo drug sensitivity testing. Relevant literature was identified through targeted searches of major biomedical databases, focusing on studies describing multi-omic predictive models, functional precision oncology platforms, and patient-derived tumor models. Results: Converging data indicate that integrated oncodiagnostic strategies can improve prediction of chemotherapy response beyond genomics-only approaches. Transcriptomic profiling captures dynamic pathway activity and resistance programs, pharmacogenetic testing informs host-specific toxicity and dosing constraints, and ex vivo assays enable direct phenotypic validation of drug efficacy. Together, these complementary approaches provide a biologically grounded framework for individualized therapy selection. Conclusions: The convergence of molecular profiling and functional phenotyping represents an emerging paradigm in precision oncology. Integrating multi-omic and functional data may enhance treatment prediction and reduce ineffective therapy, although prospective validation and standardization remain necessary for routine clinical implementation.<\/jats:p>","DOI":"10.3390\/jpm16040176","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T12:58:59Z","timestamp":1774357139000},"page":"176","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Molecular Oncodiagnostics in Precision Oncology: Integrating Tumor Transcriptomics, Patient Pharmacogenetics, and Ex Vivo Chemoresistance Testing to Improve Individual Chemotherapy Response"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9577-2585","authenticated-orcid":false,"given":"Dario","family":"Rusciano","sequence":"first","affiliation":[{"name":"Independent Researcher, 57125 Livorno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Tilsed, C.M., Fisher, S.A., Nowak, A.K., Lake, R.A., and Lesterhuis, W.J. (2022). Cancer chemotherapy: Insights into cellular and tumor microenvironmental mechanisms of action. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.960317"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1017\/pcm.2023.23","article-title":"Heterogeneity in precision oncology","volume":"2","author":"Tomasik","year":"2023","journal-title":"Camb. Prism. Precis. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/PPO.0000000000000638","article-title":"Gene expression profiles in cancers and their therapeutic implications","volume":"29","author":"Creighton","year":"2023","journal-title":"Cancer J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1158\/2159-8290.CD-23-1194","article-title":"Precision oncology: 2023 in review","volume":"13","author":"Suehnholz","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_5","first-page":"601","article-title":"Evolution of predictive risk factor analysis for chemotherapy-related toxicity","volume":"31","author":"Hertz","year":"2023","journal-title":"Support. Care Cancer"},{"key":"ref_6","first-page":"943","article-title":"Oncology\u2019s ongoing struggle with evaluating quality-of-life\u2013limiting treatment-related toxicity","volume":"33","author":"Gaynor","year":"2025","journal-title":"Support. Care Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"El-Sayed, M.M., Bianco, J.R., Li, Y., and Fabian, Z. (2024). Tumor-agnostic therapy\u2014The final step forward in the cure for human neoplasms?. Cells, 13.","DOI":"10.3390\/cells13121071"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.semcancer.2020.09.007","article-title":"Transcriptomics and solid tumors: The next frontier in precision cancer medicine","volume":"84","author":"Tsimberidou","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1158\/2159-8290.CD-22-1020","article-title":"A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment-resistant malignancies","volume":"13","author":"Mundi","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1002\/ueg2.70124","article-title":"Toward precision chemotherapy for pancreatic cancer guided by transcriptomic signatures","volume":"13","author":"Chanez","year":"2025","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_11","first-page":"315","article-title":"Modern developments in germline pharmacogenomics for oncology prescribing","volume":"72","author":"Reizine","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Hurkmans, E.G.E., Brand, A.C.A.M., Verdonschot, J.A.J., Te Loo, D.M.W.M., and Coenen, M.J.H. (2022). Pharmacogenetics of chemotherapy treatment response and toxicities in patients with osteosarcoma: A systematic review. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-10434-5"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez-Bayona, R., Catal\u00e1n, C., Cobos, M.A., and Bergamino, M. (2025). Pharmacogenomics in solid tumors: A comprehensive review of genetic variability and its clinical implications. Cancers, 17.","DOI":"10.3390\/cancers17060913"},{"key":"ref_14","first-page":"103072","article-title":"Ex vivo drug screening on patient-derived tumor material to advance functional precision in oncology: An overview on current approaches and unresolved challenges","volume":"143","author":"Mair","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Das, K., Samol, J., Khan, I.S., Ho, B., and Chuah, K.L. (2026). Integrated and Comprehensive Diagnostics: An Emerging Paradigm in Precision Oncology. Cancers, 18.","DOI":"10.3390\/cancers18020327"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Qiao, D., Wang, R.C., and Wang, Z. (2025). Precision oncology: Current landscape, emerging trends, challenges, and future perspectives. Cells, 14.","DOI":"10.20944\/preprints202510.1139.v1"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"156280","DOI":"10.1016\/j.prp.2025.156280","article-title":"Next generation DNA sequencing data analysis and its application in clinical genomics","volume":"276","author":"Beura","year":"2025","journal-title":"Pathol. Res. Pract."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13073-024-01320-9","article-title":"Single-cell profiling of response to neoadjuvant chemo-immunotherapy in surgically resectable esophageal squamous cell carcinoma","volume":"16","author":"Ji","year":"2024","journal-title":"Genome Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"9402","DOI":"10.1038\/s41467-024-53535-4","article-title":"Single-cell landscape of innate and acquired drug resistance in acute myeloid leukemia","volume":"15","author":"Wegmann","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.21037\/jgo-24-93","article-title":"Single-cell analysis of chemotherapy-resistant microenvironment identifies a chemo-response biomarker for pancreatic cancer","volume":"15","author":"Xu","year":"2024","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/14622416.2025.2571387","article-title":"Characterizing models for delivery of pharmacogenomic testing: A scoping review","volume":"26","author":"Waheed","year":"2025","journal-title":"Pharmacogenomics"},{"key":"ref_22","first-page":"142","article-title":"Emerging molecular technology in cancer testing","volume":"35","author":"Sundaresan","year":"2024","journal-title":"EJIFCC"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1186\/s12967-025-07308-2","article-title":"Exploiting artificial intelligence in precision oncology: An updated comprehensive review","volume":"23","author":"Goda","year":"2025","journal-title":"J. Transl. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1007\/s12094-024-03697-w","article-title":"Tumor microenvironment as a complex milieu driving cancer progression: A mini review","volume":"27","author":"Li","year":"2025","journal-title":"Clin. Transl. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s40291-021-00575-x","article-title":"The value of pharmacogenetics to reduce drug-related toxicity in cancer patients","volume":"26","author":"Mhandire","year":"2022","journal-title":"Mol. Diagn. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s11033-025-10887-4","article-title":"Personalizing cancer therapy: The role of pharmacogenetics in overcoming drug resistance and toxicity","volume":"52","author":"Nafchi","year":"2025","journal-title":"Mol. Biol. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s40364-020-00213-4","article-title":"Application of pharmacogenetics in oncology","volume":"8","author":"Ivanov","year":"2020","journal-title":"Biomark. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"17588359231156382","DOI":"10.1177\/17588359231156382","article-title":"A transcriptomics approach to expand therapeutic options and optimize clinical trials in oncology","volume":"15","author":"Lazar","year":"2023","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12935-015-0212-2","article-title":"Only one health, and so many omics","volume":"15","year":"2015","journal-title":"Cancer Cell Int."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Ivanisevic, T., and Sewduth, R.N. (2023). Multi-omics integration for the design of novel therapies and the identification of novel biomarkers. Proteomes, 11.","DOI":"10.3390\/proteomes11040034"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/s12935-025-03944-2","article-title":"Integration of multi-omics approaches in exploring intra-tumoral heterogeneity","volume":"25","author":"Dong","year":"2025","journal-title":"Cancer Cell Int."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Wu, Y., Chen, M., and Qin, Y. (2025). Anticancer drug response prediction integrating multi-omics pathway-based difference features and multiple deep learning techniques. PLoS Comput. Biol., 21.","DOI":"10.1371\/journal.pcbi.1012905"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/s41419-024-06960-8","article-title":"Single-cell transcriptome profiles the heterogeneity of tumor cells and microenvironments for different pathological endometrial cancer and identifies specific sensitive drugs","volume":"15","author":"Ren","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Al-Kabani, A., Huda, B., Haddad, J., Yousuf, M., Bhurka, F., Ajaz, F., Patnaik, R., Jannati, S., and Banerjee, Y. (2025). Exploring experimental models of colorectal cancer: A critical appraisal from 2D cell systems to organoids, humanized mouse avatars, organ-on-chip, CRISPR engineering, and AI-driven platforms\u2014Challenges and opportunities for translational precision oncology. Cancers, 17.","DOI":"10.3390\/cancers17132163"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1186\/s12967-023-04806-z","article-title":"Patient-derived scaffolds representing breast cancer microenvironments influence chemotherapy responses in adapted cancer cells consistent with clinical features","volume":"21","author":"Leiva","year":"2023","journal-title":"J. Transl. Med."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Goh, L.S.H., Thng, D.K.H., Ang, Y.L.E., Ho, D., Toh, T.B., and Wong, A.L.A. (2026). The functional imperative in high-grade glioma. Exp. Mol. Med., epub ahead of printing.","DOI":"10.1038\/s12276-025-01614-x"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Kolodziej, M., Czarny, J., Dyla, H., Rekawek, D., Zlotek, M., Wlodarz, A., Baranowicz, M., Kwiatkowska-Borowczyk, E., Milbrandt, O., and Ramlau, R. (2026). Breast cancer multicellular spheroid models\u2014A tool for studying cancer biology: A possible platform for drug screening and personalized medicine. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27031314"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s43556-023-00165-9","article-title":"Patient-derived organoids in human cancer: A platform for fundamental research and precision medicine","volume":"5","author":"Qu","year":"2024","journal-title":"Mol. Biomed."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.cmet.2025.10.022","article-title":"Digital twins for in vivo metabolic flux estimations in patients with brain cancer","volume":"38","author":"Meghdadi","year":"2026","journal-title":"Cell Metab."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/s43018-023-00645-5","article-title":"Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies: The prospective non-interventional SMARTrial","volume":"4","author":"Liebers","year":"2023","journal-title":"Nat. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41420-023-01722-5","article-title":"Standardized assays to monitor drug sensitivity in hematologic cancers","volume":"9","author":"Hermansen","year":"2023","journal-title":"Cell Death Discov."},{"key":"ref_42","unstructured":"ClinicalTrials.gov (2026, March 14). Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling (Identifier NCT05857969), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05857969?utm_source=chatgpt.com."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5648","DOI":"10.1038\/s41598-026-36430-4","article-title":"QAL333\u2019s antitumor activity and predictive modeling: Integrated transcriptomic-bioinformatic analysis reveals selective cytotoxicity and sensitivity determinants","volume":"16","author":"Kim","year":"2026","journal-title":"Sci. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41564-025-02217-y","article-title":"Large-scale testing of antimicrobial lethality at single-cell resolution predicts mycobacterial infection outcomes","volume":"11","author":"Jovanovic","year":"2026","journal-title":"Nat. Microbiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"9160","DOI":"10.1038\/s41598-025-93634-w","article-title":"The first-in-Africa ex vivo drug sensitivity testing platform identifies novel drug combinations for South African leukaemia patient cohort","volume":"15","author":"Kenmogne","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Deng, H., Liu, Q., Tian, Z., Liu, G., Wang, S., Liang, D., Wang, Y., Han, Y., and Xie, S. (2025). Spatial transcriptomics uncovers immune-cell plasticity and dedifferentiation signatures in aggressive lung adenocarcinoma subtypes. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1620886"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"pkaf079","DOI":"10.1093\/jncics\/pkaf079","article-title":"MammaPrint predicts chemotherapy benefit in HR+HER2\u2212 early breast cancer: FLEX Registry real-world data","volume":"9","author":"Brufsky","year":"2025","journal-title":"JNCI Cancer Spectr."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"65","DOI":"10.21037\/cco-23-96","article-title":"Twenty-five years with companion diagnostics","volume":"12","year":"2023","journal-title":"Chin. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"11772719211047763","DOI":"10.1177\/11772719211047763","article-title":"Companion diagnostics: State of the art and new regulations","volume":"16","author":"Valla","year":"2021","journal-title":"Biomark. Insights"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1586\/14737159.2014.910120","article-title":"A new generation of companion diagnostics: Cobas BRAF, KRAS and EGFR mutation detection tests","volume":"14","author":"Angulo","year":"2014","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e70162","DOI":"10.1111\/cts.70162","article-title":"Bridging gaps in oncology: Comparative analysis of development and approval pathways for anticancer drugs and companion diagnostics in the United States and Japan","volume":"18","author":"Saito","year":"2025","journal-title":"Clin. Transl. Sci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"6804","DOI":"10.1038\/s41467-021-26870-z","article-title":"Spatial and temporal intratumour heterogeneity has potential consequences for single biopsy-based neuroblastoma treatment decisions","volume":"12","author":"Schmelz","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e70171","DOI":"10.1002\/cbf.70171","article-title":"The Perspectives of Posttranslational Modifications of Nuclear Proteins in Related Physiology and Diseases Assisted With Multi-Omics Integrative Analysis and Machine Learning","volume":"44","author":"Tang","year":"2026","journal-title":"Cell Biochem. Funct."},{"key":"ref_54","unstructured":"Aman, L.A.O., Arfan, A., Asnaw, A., Putra, P.P., Hasan, H., and Papeo, D.R.P. (2025). Prediction of PLX-4720 sensitivity in cancer cell lines through multi-omics integration and attention-based fusion modeling. arXiv."},{"key":"ref_55","first-page":"4","article-title":"Digital twins to personalize medicine","volume":"12","author":"Borrebaeck","year":"2019","journal-title":"Genome Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41746-024-01073-0","article-title":"Digital twins for health: A scoping review","volume":"7","author":"Katsoulakis","year":"2024","journal-title":"NPJ Digit. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"100056","DOI":"10.1016\/j.esmorw.2024.100056","article-title":"Digital twins: A new paradigm in oncology in the era of big data","volume":"5","author":"Mollica","year":"2024","journal-title":"ESMO Real World Data Digit. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Silva, A., and Vale, N. (2025). Digital Twins in Personalized Medicine: Bridging Innovation and Clinical Reality. J. Pers. Med., 15.","DOI":"10.3390\/jpm15110503"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Baranovskii, A., G\u00fcnd\u00fcz, I.B., Franke, V., Uyar, B., and Akalin, A. (2022). Multi-omics alleviates the limitations of panel sequencing for cancer drug response prediction. Cancers, 14.","DOI":"10.1101\/2022.06.15.496249"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.ccell.2022.08.011","article-title":"Clinical application of advanced multi-omics tumor profiling: Shaping precision oncology of the future","volume":"40","author":"Akhoundova","year":"2022","journal-title":"Cancer Cell"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/978-1-0716-3163-8_7","article-title":"Integration of single-cell RNA-sequencing and network analysis to investigate mechanisms of drug resistance","volume":"2660","author":"The","year":"2023","journal-title":"Methods Mol. Biol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"110269","DOI":"10.1016\/j.celrep.2021.110269","article-title":"A functional module states framework reveals transcriptional states for drug and target prediction","volume":"38","author":"Qin","year":"2022","journal-title":"Cell Rep."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"eabo5987","DOI":"10.1126\/scitranslmed.abo5987","article-title":"Pharmacogenomic landscape of head and neck squamous cell carcinoma informs precision oncology therapy","volume":"14","author":"Gu","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s10238-025-01694-z","article-title":"Personalized drug stratification using endoscopic samples to assess ex vivo gastric cancer tissue susceptibility to chemotherapy and immune checkpoint inhibitors","volume":"25","author":"Hennig","year":"2025","journal-title":"Clin. Exp. Med."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Schoonbeek, M.C., Gestraud, P., Vernooij, L., Boltjes, A., Amo-Addae, V., van Luik, M., Del Nery, E., Bellini, A., Chua, E., and Swaak, S. (2026). Ex vivo drug sensitivity profiling to complement molecular profiling in pediatric precision oncology. NPJ Precis. Oncol.","DOI":"10.1038\/s41698-025-01266-0"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1126\/science.aao2774","article-title":"Patient-derived organoids model treatment response of metastatic gastrointestinal cancers","volume":"359","author":"Vlachogiannis","year":"2018","journal-title":"Science"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"eaay2574","DOI":"10.1126\/scitranslmed.aay2574","article-title":"Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients","volume":"11","author":"Ooft","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/s41591-019-0424-4","article-title":"Genomic and transcriptomic profiling expands precision cancer medicine: The WINTHER trial","volume":"25","author":"Rodon","year":"2019","journal-title":"Nat. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1038\/s41591-025-03715-6","article-title":"Feasibility of multiomics tumor profiling for guiding treatment of melanoma","volume":"31","author":"Miglino","year":"2025","journal-title":"Nat. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e2500896","DOI":"10.1200\/PO-25-00896","article-title":"Safety of Multi-Omics-Guided Therapy in Advanced Melanoma: A Matched Comparative Cohort Analysis","volume":"10","author":"Gosztonyi","year":"2026","journal-title":"JCO Precis. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1053\/j.gastro.2024.05.032","article-title":"Organoids for Functional Precision Medicine in Advanced Pancreatic Cancer","volume":"167","author":"Cartry","year":"2024","journal-title":"Gastroenterology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.trecan.2025.03.005","article-title":"The future of tumor organoids in precision therapy","volume":"11","author":"Kim","year":"2025","journal-title":"Trends Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1002\/cpt.3355","article-title":"Real-World Evidence to Support EU Regulatory Decision Making-Results From a Pilot of Regulatory Use Cases","volume":"116","author":"Prilla","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"5015","DOI":"10.1158\/1078-0432.CCR-25-1564","article-title":"Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer","volume":"31","author":"Smabers","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/1878-0261.13191","article-title":"Ex vivo drug sensitivity screening in multiple myeloma identifies drug combinations that act synergistically","volume":"16","author":"Giliberto","year":"2022","journal-title":"Mol. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"102226","DOI":"10.1016\/j.tranon.2024.102226","article-title":"Patient-derived tumor organoids: A preclinical platform for personalized cancer therapy","volume":"51","author":"Taurin","year":"2025","journal-title":"Transl. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s13046-023-02853-4","article-title":"Implementing patient-derived organoids in functional precision medicine for patients with advanced colorectal cancer","volume":"42","author":"Cartry","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41698-024-00517-w","article-title":"New regulatory thinking is needed for AI-based personalised drug and cell therapies in precision oncology","volume":"8","author":"Derraz","year":"2024","journal-title":"NPJ Precis. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s13046-024-03173-x","article-title":"Challenges in validation of combination treatment strategies for CRC using patient-derived organoids","volume":"43","author":"Benboubker","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Tsukamoto, Y., Hirashita, Y., Shibata, T., Fumoto, S., Kurogi, S., Nakada, C., Kinoshita, K., Fuchino, T., Murakami, K., and Inomata, M. (2023). Patient-derived ex vivo cultures and endpoint assays with surrogate biomarkers in functional testing for prediction of therapeutic response. Cancers, 15.","DOI":"10.3390\/cancers15164104"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Motohashi, S., Katsuta, E., and Ban, D. (2025). Advances and challenges in drug screening for cancer therapy: A comprehensive review. Bioengineering, 12.","DOI":"10.3390\/bioengineering12121315"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41698-024-00528-7","article-title":"Delineating functional and molecular impact of ex vivo sample handling in precision medicine","volume":"8","author":"Struyf","year":"2024","journal-title":"NPJ Precis. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Guo, L., Li, C., and Gong, W. (2024). Toward reproducible tumor organoid culture: Focusing on standardization and reproducibility challenges. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1290504"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Ji, M., Zhao, J.Y., Wang, H.F., Wang, C.W., Li, W., Ye, J.J., Lu, F., Lin, L.H., and Gao, Y.T. (2022). Ex vivo chemosensitivity profiling of acute myeloid leukemia and its correlation with clinical response and outcome to chemotherapy. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.793773"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Ladan, M.M., Meijer, T.G., Verkaik, N.S., Komar, Z.M., van Deurzen, C.H.M., den Bakker, M.A., Kanaar, R., van Gent, D.C., and Jager, A. (2022). Functional ex vivo tissue-based chemotherapy sensitivity testing for breast cancer. Cancers, 14.","DOI":"10.3390\/cancers14051252"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41523-023-00583-6","article-title":"Proof-of-concept study linking ex vivo sensitivity testing to neoadjuvant anthracycline-based chemotherapy response in breast cancer patients","volume":"9","author":"Ladan","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41378-021-00277-8","article-title":"Tumor-on-a-chip: From bioinspired design to biomedical application","volume":"7","author":"Liu","year":"2021","journal-title":"Microsyst. Nanoeng."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Gon\u00e7alves, I.M., Carvalho, V., Rodrigues, R.O., Pinho, D., Teixeira, S.F.C.F., Moita, A., Hori, T., Kaji, H., Lima, R., and Minas, G. (2022). Organ-on-a-chip platforms for drug screening and delivery in tumor cells: A systematic review. Cancers, 14.","DOI":"10.3390\/cancers14040935"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1039\/D4LC01043D","article-title":"Cancer-on-a-chip for precision cancer medicine","volume":"25","author":"Liu","year":"2025","journal-title":"Lab Chip"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.7150\/thno.122552","article-title":"Functional material probes and advanced technologies in organ-on-a-chip characterization","volume":"16","author":"Wang","year":"2026","journal-title":"Theranostics"}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/16\/4\/176\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T13:36:34Z","timestamp":1774359394000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/16\/4\/176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":90,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["jpm16040176"],"URL":"https:\/\/doi.org\/10.3390\/jpm16040176","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]}}}